Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress
Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress
Oak Ridge, TN, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Society for Critical Care Medicine (SCCM) 2024 Critical Care Congress at the Phoenix Convention Center in Phoenix, AZ from January 21 through January 23, 2024.
田納西州橡樹嶺，2024 年 1 月 16 日（GLOBE NEWSWIRE）— 達克索公司 （納斯達克股票代碼：DXR），血容量測量技術的全球領導者，今天宣佈將於2024年1月21日至1月23日在亞利桑那州鳳凰城會議中心參加2024年重症醫學協會（SCCM）重症監護大會。
Highlighting the significance of this meeting as the leading critical care conference globally and presenting a substantial opportunity for Daxor to extend its presence within this specialized field, Michael Feldschuh, Daxor's CEO and President, said, "Our diagnostic has shown its value in guiding care to optimal volume in areas such as heart failure and critical care. This conference allows us to reach providers and healthcare systems for whom effective volume management poses a significant challenge, and stand to benefit from both a patient outcome and health economic perspective by adopting our solutions."
達克索首席執行官兼總裁邁克爾·費爾德舒強調了本次會議作爲全球領先的重症監護會議的重要性，併爲達克索擴大其在該專業領域的影響力提供了重要機會，他說：“我們的診斷已顯示出其在指導心力衰竭和重症監護等領域的護理達到最佳水平方面的價值。這次會議使我們能夠接觸到有效的容量管理構成重大挑戰的提供商和醫療保健系統，並通過採用我們的解決方案，將從患者預後和健康經濟的角度中受益。”
Daxor's Chief Scientific Officer Jonathan Feldschuh added, "We have demonstrated compelling evidence affirming the efficacy of direct blood volume measurement in enhancing patient outcomes within critical care settings. Peer-reviewed studies, including a randomized controlled trial, have shown that actionable insights from the BVA-100 (Blood Volume Analyzer) significantly altered fluid and red blood cell interventions in 44% of cases within surgical intensive care units, leading to a remarkable 66% decrease in patient mortality. Furthermore, these interventions resulted in reduced patient hospital stays and fewer days spent on a ventilator."
達克索首席科學官喬納森·費爾德舒補充說：“我們已經展示了令人信服的證據，證實了直接血容量測量在重症監護環境中改善患者預後方面的功效。經過同行評審的研究，包括一項隨機對照試驗，都表明，BVA-100 提供了切實可行的見解 （血容量分析器）顯著改變了外科重症監護室中44％的病例的液體和紅細胞干預措施，使患者死亡率顯著下降了66％。此外，這些干預措施減少了患者的住院時間，減少了在呼吸機上花費的天數。”
The Company will be exhibiting at Booth #936.
該公司將在 #936 號展位展出。
About Society of Critical Care Medicine
重症監護醫學學會簡介
The Society of Critical Care Medicine (SCCM) is the largest nonprofit medical organization dedicated to promoting excellence and consistency in the practice of critical care. With members in more than 80 countries, SCCM is the only organization that represents all professional components of the critical care team. SCCM's Critical Care Congress brings together intensivists and critical care experts from around the world to share the latest scientific research, develop solutions to common issues, and improve the care of critically ill and injured patients.
重症監護醫學會（SCCM）是最大的非營利性醫療組織，致力於促進重症監護實踐的卓越性和一致性。SCCM 的成員遍佈 80 多個國家，是唯一一個代表重症監護團隊所有專業組成部分的組織。SCCM的重症監護大會彙集了來自世界各地的重症監護專家和重症監護專家，分享最新的科學研究，爲常見問題制定解決方案，並改善對重症和受傷患者的護理。
About Daxor Corporation
關於達克索公司
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor's innovative technology HERE.
達克索公司（納斯達克股票代碼：DXR）是血容量測量技術的全球領導者，專注於血容量測試創新。我們開發並銷售 BVA-100 （血容量分析器），唯一獲得 FDA 批准的診斷性血液檢測，可提供與患者特定標準相比，安全、準確、客觀的血容量狀態和成分定量。在美國各地的領先醫院中心進行了超過65,000次檢查，提高了醫院在各種外科和醫療條件下的績效指標，包括顯著降低心力衰竭和重症監護的死亡率和再入院率。Daxor在美國國立衛生研究院的支持下，正在進行多項心力衰竭治療領域的試驗，並與美國國防部簽訂了開發分析儀以改善戰鬥傷員護理的合同。Daxor 的使命是通過血容量分析實現最佳的液體管理來推進醫療保健。Daxor 的視力是所有人的最佳血容量。欲了解更多信息，請訪問我們的網站 daxor.com。註冊接收有關 Daxor 創新技術的新聞 這裏。
Forward-Looking Statements
前瞻性陳述
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
本新聞稿中的某些陳述可能包括1995年《私人證券訴訟改革法》所指的前瞻性陳述，包括但不限於有關僱用銷售人員和擴大分銷渠道的影響的陳述。前瞻性陳述是基於當前預期和假設的關於未來事件的預測、預測和其他陳述，因此受風險和不確定性的影響。許多因素可能導致未來的實際事件與本新聞稿中的前瞻性陳述存在重大差異，包括但不限於與我們的上市後臨床數據收集活動相關的風險、我們的產品對患者的好處、我們對產品開發和商業化工作的期望、我們提高市場和醫生對我們產品的接受度的能力、潛在的競爭產品供應、知識產權保護、美國食品藥品管理局的監管行動、我們整合收購的能力業務、我們對與被收購企業的預期協同效應和收益的預期，以及我們在向美國證券交易委員會提交的文件中描述的其他風險和不確定性。前瞻性陳述僅代表截至發表之日。無論是由於新信息、未來事件還是其他原因，Daxor不承擔任何公開更新或修改任何前瞻性陳述的義務。
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
516-222-2560
brets@coreir.com
投資者關係聯繫人：
佈雷特·夏皮羅
CORE IR 高級管理合夥人
516-222-2560
brets@coreir.com
譯文內容由第三人軟體翻譯。